Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
Boziki MK, Karapanayotides T, Papadopoulos G, Lagoudaki R, Melo P, Bakirtzis C, Nikolaidis I, Gounari E, Tsavdaridou V, Skoura L, Afrantou T, Tatsi T, Grigoriadou E, Polyzoidou E, Mandoras N, Giantzi V, Kalogera-Fountzila A, Ioannidis P, Parissis D, Pelidou SH, Zoidou S, Grigoriadis N. Boziki MK, et al. Among authors: giantzi v. Neurol Res. 2020 Mar;42(3):209-221. doi: 10.1080/01616412.2020.1722913. Epub 2020 Feb 12. Neurol Res. 2020. PMID: 32048570
Estimating Everyday Neuropsychological Functioning in Multiple Sclerosis: Reliability and Validity of the Greek Multiple Sclerosis Neuropsychological Questionnaire.
Konstantinopoulou E, Ioannidis P, Bakirtzis C, Giantzi V, Afrantou T, Parissis D, Messinis L, Nasios G, Grigoriadis N. Konstantinopoulou E, et al. Among authors: giantzi v. Mult Scler Int. 2018 Sep 25;2018:6301535. doi: 10.1155/2018/6301535. eCollection 2018. Mult Scler Int. 2018. PMID: 30356376 Free PMC article.
Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center.
Boziki M, Bakirtzis C, Giantzi V, Sintila SA, Kallivoulos S, Afrantou T, Nikolaidis I, Ioannidis P, Karapanayiotides T, Koutroulou I, Parissis D, Grigoriadis N. Boziki M, et al. Among authors: giantzi v. Front Neurol. 2021 Aug 23;12:699844. doi: 10.3389/fneur.2021.699844. eCollection 2021. Front Neurol. 2021. PMID: 34497577 Free PMC article.
Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response.
Boziki M, Bakirtzis C, Sintila SA, Kesidou E, Gounari E, Ioakimidou A, Tsavdaridou V, Skoura L, Fylaktou A, Nikolaidou V, Stangou M, Nikolaidis I, Giantzi V, Karafoulidou E, Theotokis P, Grigoriadis N. Boziki M, et al. Among authors: giantzi v. Cells. 2022 Jun 17;11(12):1959. doi: 10.3390/cells11121959. Cells. 2022. PMID: 35741088 Free PMC article.
The Experience of a Tertiary Reference Hospital in the Study of Rare Neurological Diseases.
Sintila SA, Boziki M, Bakirtzis C, Stardeli T, Smyrni N, Nikolaidis I, Parissis D, Afrantou T, Karapanayiotides T, Koutroulou I, Giantzi V, Theotokis P, Kesidou E, Xiromerisiou G, Dardiotis E, Ioannidis P, Grigoriadis N. Sintila SA, et al. Among authors: giantzi v. Medicina (Kaunas). 2023 Jan 30;59(2):266. doi: 10.3390/medicina59020266. Medicina (Kaunas). 2023. PMID: 36837468 Free PMC article.
15 results